HUP0302333A2 - Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására - Google Patents
Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállításáraInfo
- Publication number
- HUP0302333A2 HUP0302333A2 HU0302333A HUP0302333A HUP0302333A2 HU P0302333 A2 HUP0302333 A2 HU P0302333A2 HU 0302333 A HU0302333 A HU 0302333A HU P0302333 A HUP0302333 A HU P0302333A HU P0302333 A2 HUP0302333 A2 HU P0302333A2
- Authority
- HU
- Hungary
- Prior art keywords
- copolymer
- treatment
- nervous system
- central nervous
- preparation
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title abstract 2
- 208000015114 central nervous system disease Diseases 0.000 title abstract 2
- 229920001577 copolymer Polymers 0.000 title abstract 2
- 229960003776 glatiramer acetate Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány glatiramer-acetát (kopolimer 1) alkalmazására vonatkozikegy gyulladásos, nem autoimmun központi idegrendszeri betegségkezelésére vagy egy ilyen betegség tüneteinek enyhítésére szolgálógyógyszerkészítmény előállítására. A találmány további tárgya aglatiramer-acetát alkalmazása egy mátrix metalloproteinázaktivitásának gátlására szolgáló gyógyszerkészítmény és egy citokinaktivált T-limfociták általi termelésének szuppresszálására szolgálógyógyszerkészítmény előállítására. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58752300A | 2000-06-05 | 2000-06-05 | |
PCT/US2001/018248 WO2001093828A1 (en) | 2000-06-05 | 2001-06-05 | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0302333A2 true HUP0302333A2 (hu) | 2003-11-28 |
HUP0302333A3 HUP0302333A3 (en) | 2005-07-28 |
Family
ID=24350145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0302333A HUP0302333A3 (en) | 2000-06-05 | 2001-06-05 | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1292279A4 (hu) |
JP (1) | JP2003535118A (hu) |
AU (2) | AU7528001A (hu) |
CA (1) | CA2411536A1 (hu) |
HU (1) | HUP0302333A3 (hu) |
IL (1) | IL153236A0 (hu) |
PL (1) | PL363431A1 (hu) |
WO (1) | WO2001093828A1 (hu) |
ZA (1) | ZA200210084B (hu) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
WO2003048735A2 (en) | 2001-12-04 | 2003-06-12 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
US7560100B2 (en) | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
CZ30474U1 (cs) | 2009-08-20 | 2017-03-14 | Yeda Research And Development Co., Ltd. | Glatiramer acetát a terapeutická kompozice s jeho obsahem pro použití k léčení s nízkou frekvencí ošetření |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記 |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
EP3185882B1 (en) | 2014-08-29 | 2019-10-09 | Aarhus Universitet | Positively charged co-polymers for use as antimicrobial agents |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
CN106924175B (zh) * | 2015-12-29 | 2020-07-03 | 深圳翰宇药业股份有限公司 | 一种治疗多发性硬化症的药物组合物 |
JP2019519515A (ja) | 2016-05-20 | 2019-07-11 | シーダーズ—シナイ メディカル センター | アルツハイマー病およびアルツハイマー病に関係する疾病を処置または予防する方法 |
EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
GB9411292D0 (en) * | 1994-06-06 | 1994-07-27 | Teva Pharma | Pharmaceuticals compositions |
US5665764A (en) * | 1995-06-02 | 1997-09-09 | Warner-Lambert Company | Tricyclic inhibitors of matrix metalloproteinases |
IL119989A0 (en) * | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
WO2001052878A2 (en) * | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
US20020037848A1 (en) * | 2000-06-07 | 2002-03-28 | Michal Eisenbach-Schwartz | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
-
2001
- 2001-06-05 HU HU0302333A patent/HUP0302333A3/hu unknown
- 2001-06-05 JP JP2002501401A patent/JP2003535118A/ja active Pending
- 2001-06-05 IL IL15323601A patent/IL153236A0/xx unknown
- 2001-06-05 WO PCT/US2001/018248 patent/WO2001093828A1/en not_active Application Discontinuation
- 2001-06-05 PL PL01363431A patent/PL363431A1/xx not_active Application Discontinuation
- 2001-06-05 EP EP01941973A patent/EP1292279A4/en not_active Withdrawn
- 2001-06-05 AU AU7528001A patent/AU7528001A/xx active Pending
- 2001-06-05 AU AU2001275280A patent/AU2001275280B2/en not_active Ceased
- 2001-06-05 CA CA002411536A patent/CA2411536A1/en not_active Abandoned
-
2002
- 2002-12-12 ZA ZA200210084A patent/ZA200210084B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU7528001A (en) | 2001-12-17 |
WO2001093828A1 (en) | 2001-12-13 |
EP1292279A4 (en) | 2005-01-12 |
CA2411536A1 (en) | 2001-12-13 |
EP1292279A1 (en) | 2003-03-19 |
PL363431A1 (en) | 2004-11-15 |
HUP0302333A3 (en) | 2005-07-28 |
AU2001275280B2 (en) | 2006-03-16 |
IL153236A0 (en) | 2003-07-06 |
JP2003535118A (ja) | 2003-11-25 |
ZA200210084B (en) | 2003-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0302333A2 (hu) | Glatiramer-acetát (kopolimer 1) alkalmazása központi idegrendszeri rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására | |
HUP0200714A2 (hu) | Gyógyhatású vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0204023A2 (hu) | Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303340A2 (hu) | Eljárások gyulladásos vagy autoimmun rendellenességek megelőzésére vagy kezelésére integrin alfa-v-béta-3 antagonisták más profilaktikusan vagy terápiásan hatásos ágensekkel kombinált beadásával | |
NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
PL1635824T3 (pl) | 5-Członowe heterocykliczne inhibitory P-38 | |
HUP0303363A2 (hu) | Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
NO20052739L (no) | CCR5-antagonister som medikamenter | |
CA2408142A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
HUP0400659A2 (hu) | Kitinázokkal, kitinázszerű molekulákkal és gyulladásos megbetegedéssel kapcsolatos eljárások, készítmények és reagenskészletek | |
HUP0103542A2 (hu) | Opioid-receptor aktivitással rendelkező 4,4-biaril-piperidin származékok és a vegyületeket tartalmazó gyógyászati készítmények | |
EP2213684A3 (en) | Nogo-a antibodies for the treatment of Alzheimer disease | |
DE69920757D1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
YU25399A (sh) | 6-fenilpiridil-2-amino derivati korisni kao nos inhibitori | |
FR2700117B1 (fr) | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. | |
MY133393A (en) | Phenyl xanthine derivatives | |
DE60322423D1 (de) | Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten | |
HUP0402422A2 (hu) | Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
AU2002307049A1 (en) | Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia | |
GB0111186D0 (en) | Novel compounds | |
HUP0103781A2 (hu) | Megismerési képesség javítására szolgáló gyógyszerkészítmények, melyek atipikus antipszihotikus szer és acetilkolinészteráz inhibitor kombinációját tartalmazzák | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
HUP0400386A2 (hu) | Cetirizint és pszeudoefedrint tartalmazó tabletta és alkalmazása gyógyszerkészítmények előállítására |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |